Maze Therapeutics, Inc.
MAZE
$13.71
$0.403.01%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -98.48% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -98.48% | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -98.48% | -- | -- | -- | -- |
| SG&A Expenses | 23.20% | 13.19% | 7.36% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.14% | 15.65% | 11.53% | -- | -- |
| Operating Income | -298.90% | 149.49% | 158.43% | -- | -- |
| Income Before Tax | -313.03% | 149.01% | 153.18% | -- | -- |
| Income Tax Expenses | -132.10% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -318.68% | 147.93% | 152.02% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -318.68% | 147.93% | 152.02% | -- | -- |
| EBIT | -298.90% | 149.49% | 158.43% | -- | -- |
| EBITDA | -283.46% | 154.63% | 164.45% | -- | -- |
| EPS Basic | 72.18% | 105.10% | 103.29% | -- | -- |
| Normalized Basic EPS | -186.00% | 185.25% | 161.92% | -- | -- |
| EPS Diluted | 74.46% | 96.42% | 96.41% | -- | -- |
| Normalized Diluted EPS | -12,752.09% | 124.55% | 99.75% | -- | -- |
| Average Basic Shares Outstanding | 726.40% | 288.88% | 4.74% | -- | -- |
| Average Diluted Shares Outstanding | 585.31% | 309.75% | 25.77% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |